Narrative review of anti-obesity drugs in longevity and aesthetic medicine
This narrative review reports that anti-obesity medications reduce major cardiovascular events, slow kidney and liver disease progression and lower all-cause mortality in selected populations, while exploratory biomarker analyses suggest effects partly independent of weight loss but do not establish slowed ageing. [1]
Automatic summary · not editorially reviewed
The key findings
The narrative review searched PubMed, EMBASE, Scopus, Web of Science, the Cochrane Library and clinical trial registries for January 2010 to June 2026. [1]
The review reports that these medications reduce major cardiovascular events, slow kidney and liver disease progression and lower all-cause mortality in selected populations. [1]
Exploratory proteomic and epigenetic analyses suggest effects partly independent of weight loss, but the review states these do not establish slowed ageing. [1]
The source at a glance
- Study type / format
- Narrative review (abstract)
- Population / context
- Selected populations in cardiovascular, renal and other studies of anti-obesity medications, as summarised in the review
- Summary based on
- Study abstract
- Original publication
- August 3, 2026
Review scope: drugs, databases and 2010–2026 window
The review covers anti-obesity medications led by the GLP-1 receptor agonists semaglutide and liraglutide and the dual GIP/GLP-1 receptor agonist tirzepatide. It searched PubMed, EMBASE, Scopus, Web of Science, the Cochrane Library and clinical trial registries for January 2010 to June 2026. It integrates mechanistic studies, randomised cardiovascular and renal outcome trials, ageing-biomarker analyses, body-composition data and patient-facing aesthetic phenomena. The stated question is whether these agents' effects reach ageing biology and appearance.
Supporting source [1]
Reported outcome-trial benefits and exploratory biomarker signals
According to the review, the evidence indicates that these medications reduce major cardiovascular events, slow kidney and liver disease progression and lower all-cause mortality in selected populations. Exploratory proteomic and epigenetic analyses further suggest effects partly independent of weight loss, though the review states these do not establish slowed ageing. Newer multi-receptor agents are described as acting with greater metabolic specificity: glucagon-containing agents such as survodutide and the triple agonist retatrutide preferentially reduce visceral and hepatic fat, with liver-fat reductions of roughly 60–80% in places. The review calls this quality of weight loss arguably more relevant to healthspan than its quantity.
Supporting source [1]
Appearance and lean-mass changes with rapid large weight loss
The review notes that rapid large-magnitude weight loss drives soft-tissue and appearance changes colloquially termed "Ozempic face" and "Ozempic body", alongside accelerated skin laxity and loss of lean mass. It adds that the lean-mass loss is tempered by data showing lean-loss proportions comparable to established agents. These aesthetic and body-composition observations are described alongside, not as proof of, effects on ageing biology.
Supporting source [1]
How to interpret this
This is a narrative review; the abstract does not report a systematic search protocol, study numbers, effect sizes or certainty assessments, and the full text was not reviewed. The biomarker findings are described as exploratory and do not establish slowed ageing.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Bijoch J. · europepmc.org · August 3, 2026